AOD-9604 vs Ipamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Key Comparison Insights
- AOD-9604 is categorized as Weight Loss, while Ipamorelin is Growth Hormone.
Detailed Comparison
| Attribute | AOD-9604 | Ipamorelin |
|---|---|---|
| Category | Weight Loss | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells. | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 200-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection |
| Typical Duration | 12-24 weeks in studies | 8-12 weeks typical |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects. | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. |
Frequently Asked Questions: AOD-9604 vs Ipamorelin
What is the difference between AOD-9604 and Ipamorelin?
AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Ipamorelin?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Ipamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Ipamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Ipamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of AOD-9604 and Ipamorelin is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.